In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Bloomberg
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE).
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioSpace
Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.
Visit: Inspiring, Exciting, Unforgettable: Fueling Innovation in Science
Inspiring, Exciting, Unforgettable: Fueling Innovation in Science
Chemistry Views
Even in case of a large chemical or pharmaceutical company, 99.99 % of all scientists work outside of the organization. So, as a company, how can you increase the percentage of scientists involved in generating new ideas? And how do you attract the best minds to participate?
Visit: Johnson & Johnson sucht Innovationen in DĂĽsseldorf, Heidelberg und MĂĽnchen
Johnson & Johnson sucht Innovationen in DĂĽsseldorf, Heidelberg und MĂĽnchen
Transkript
Das Innovationsteam von Johnson & Johnson in Europa hat in der vergangenen Woche den drei “fĂĽhrenden Ă–kosystemen der Biowissenschaften in Deutschland” (so die Eigendarstellung des Unternehmens) einen Besuch abgestattet. Man wollte sich persönlich in DĂĽsseldorf, Heidelberg und MĂĽnchen mit Unternehmern, Akademikern, TechnologietransferbĂĽros und anderen fĂĽhrenden Köpfen der Biowissenschaften treffen.
Visit: German company expansions reflect European country’s strong trade, business ties to CT
German company expansions reflect European country’s strong trade, business ties to CT
Hartford Business Journal
German biomedical institute BioMed X recently launched its first operation in New Haven, which will focus on immunology and tissue engineering research. BioMed will employ six researchers located near Yale University.
Visit: Five German Companies Announce Expansions in Connecticut
Five German Companies Announce Expansions in Connecticut
PR Newswire
AdvanceCT today announced that several German companies recently expanded their business or started expansion projects in Connecticut, including TRUMPF, BioMed X, Roehm, BYK North America and Eppendorf North America.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches New Global Call for Applications: Identification of Active Small Molecules for Drug Discovery
AION Labs, In Continued Partnership with BioMed X, Launches New Global Call for Applications: Identification of Active Small Molecules for Drug Discovery
Yahoo! Finance
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research and technology talent for new startup focused on: “AI-Powered Drug Discovery of New High-Affinity Small Molecules”.
Visit: AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery
AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery
Pharmaceutical Technology
The new startup will utilise cutting-edge methods to accelerate drug discovery research.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioSpace
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Wall Street Online
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Yahoo! Finance
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model launched today – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Access Wire
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on wound healing & fibrosis.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Open PR
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
PharmiWeb
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Access Wire
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Finanz Nachrichten
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of its new research project – “New Strategies to Enhance the Immunogenicity of Tumors” – in collaboration with Merck. The focus of this new research group will be to develop novel approaches for enhancing tumor immunogenicity to broaden the population of patients who could benefit from cancer immunotherapy.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioSpace
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
StartupHub.ai
AION Labs, a pioneering innovation lab dedicated to utilizing AI technologies and computational science for tackling therapeutic challenges, and BioMed X, an independent German research institute, have announced their 2023 global call for applications. They are seeking talented technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
PR Newswire
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
BioSpace
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”